PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Immunoglobulin replacement therapy shows no reduction in serious infections for patients with CLL

Findings at odds with increasing use of the therapy in clinical practice

2025-07-31
(Press-News.org) (WASHINGTON, July 31, 2025) — In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, according to a study published in Blood Advances.

“This is the first large, real-world study to follow patients with CLL who are regularly receiving immunoglobulin replacement,” said lead study author Sara Carrillo de Albornoz, health economist and a PhD candidate at Monash University in Australia. “Given its high cost and variable use in clinical practice, this is a critical issue from a policy, economic, and clinical perspective.”

CLL, a common type of leukemia in adults, disrupts the body’s production of antibodies (immunoglobulin molecules) that fight infections. As a result, patients with CLL are often susceptible to serious and potentially life-threatening infections. Treatment with immunoglobulin replacement therapy is often used to boost antibody levels in an effort to reduce infection risk.

“Many of the studies supporting the use of immunoglobulins to reduce infections in patients with blood cancers date back over thirty years, and the treatment for CLL has advanced significantly since then,” said study author Erica Wood, AO, MD, professor at Monash University. “While immunoglobulins likely do benefit some patients, there remains a critical need to better understand the extent of that benefit, who is most likely to benefit, and how long these patients should be receiving treatment.”

The research team used linked data from the Victorian Cancer Registry, Death Index, and Admitted Episodes Dataset, which included longitudinal hospital and death data for patients aged 18 years and older who had been diagnosed with CLL between January 1, 2008, and December 31, 2022, in Victoria, Australia. The total study cohort was 6,217 patients, with 5,464 (87.9%) not having received immunoglobulin replacement therapy and 753 (12.1%) having received at least one dose during their follow-up period, which averaged 6.9 years.

Over the entire 14-year follow-up period, among patients who remained alive, the proportion of those receiving immunoglobulin replacement therapy increased from 2% in the first year after diagnosis to 8.8% by year 14. During this time, 2,191 of the 6,217 (35.2%) patients died, with a median time to death from diagnosis of approximately ten years. Among the full study cohort, patients who had a serious infection were much more likely to begin receiving immunoglobulin replacement therapy in the 30 days following their infection, at a rate of 0.075 per person-month (a unit measuring incidence per each person observed for a month), compared to just 0.001 per person-month for those without a serious infection. Of the 753 patients who started immunoglobulin replacement therapy, 346 (45.9%) died during follow-up, with a median survival of approximately six years from first treatment. Consistent with the overall study cohort, recipients of immunoglobulin replacement therapy who had been hospitalized for a serious infection in the past month showed a higher 30-day mortality rate per person-month compared to those without infections (0.090 vs.0.008, respectively) – highlighting the significant impact of infections as a leading cause of death for patients with CLL.

Despite the increasing use of immunoglobulin replacement therapy over the study period, the rate of serious infections requiring hospitalization increased from 1.9% to 3.9%. The researchers also noted that, among patients receiving immunoglobulins regularly, there was a significantly higher incidence of infection while on immunoglobulin replacement therapy compared to off-treatment periods (0.056 vs. 0.038 infections per person-month, respectively). Among patients on regular immunoglobulins, 46.9% remained on treatment from one to five years, and 23.5% received immunoglobulins for more than five years, conditional on follow-up and survival.

“We not only saw no reduction in infection rates or hospitalizations among patients receiving immunoglobulins, we found that many were on this therapy for extended periods of time,” said Dr. Wood. “It’s essential that we evaluate how long these patients remain on treatment and why to avoid unnecessary, prolonged, and expensive therapy of a product in limited supply internationally.”

Immunoglobulins are typically administered intravenously in a hospital setting, although at-home subcutaneous infusions are increasing in popularity. The therapy’s high cost is largely driven by its complex manufacturing process and compounded by the frequency of treatment; for patients with CLL, intravenous immunoglobulins are generally administered on a monthly basis. In Australia, where this study took place, the cost of immunoglobulin is fully subsidized by the government, but in the United States and other countries, the financial burden can be significant.

“The cost of this therapy, its burden to patients, and the patterns of use and infection we observed are a clear call for better guidelines on the use of immunoglobulins,” said Ms. Carrillo. “Although there are criteria for access to government-funded therapy in this population in Australia, clear clinical guidelines are lacking.”

The study has some limitations given its retrospective nature, namely potential selection bias and incomplete data, particularly around clinical prognostic factors, disease severity, and cancer treatment. Additionally, there were significant differences at baseline between compared patient groups, specifically those who did and did not receive immunoglobulins and those who received it regularly versus intermittently.

The researchers currently have follow-up studies underway, including a clinical trial comparing immunoglobulins and antibiotics for infection prevention in patients with CLL, non-Hodgkin lymphoma, and multiple myeloma, and studies looking at the cost of immunoglobulins and serious infections for patients with blood cancers.  

###

Blood Advances (bloodadvances.org) is an online, open-access journal publishing more peer-reviewed hematology research than any other academic journal worldwide. Blood Advances is part of the Blood journals portfolio (bloodjournals.org) from the American Society of Hematology (ASH) (hematology.org).
 

END


ELSE PRESS RELEASES FROM THIS DATE:

University of Colorado Anschutz Medical Campus awarded one of the largest clinical trial grants in campus history to lead trauma study

2025-07-31
AURORA, Colo. (July 31, 2025) – The University of Colorado Anschutz Medical Campus will lead a groundbreaking national clinical trial—supported by a $29 million grant from Octapharma—to evaluate whether early replacement of fibrinogen, a critical blood clotting mechanism in the body, can improve outcomes for trauma patients experiencing life-threatening bleeding. This investigator-initiated study is one of the largest clinical trial grants in campus history. The EFFECT Trial (Early ...

Weather-tracking advances are revealing astonishing extremes of lightning

2025-07-31
It was a single lightning flash that streaked across the Great Plains for 515 miles, from eastern Texas nearly all the way to Kansas City, setting a new world record. “We call it megaflash lightning and we're just now figuring out the mechanics of how and why it occurs,” said Randy Cerveny, an Arizona State University President’s Professor in the School of Geographical Sciences and Urban Planning. Cerveny and colleagues used space-based instruments to measure the megaflash, which took place during a major thunderstorm in October 2017. Its astonishing horizontal reach surpasses by 38 miles the previous record of 477 miles recorded during ...

Grasses are spendthrifts, forests are budgeters, in a nuanced account of plant water use

2025-07-31
(Santa Barbara, Calif.) — Even a toddler knows that plants need water. It’s perhaps the first thing we learn about these green lifeforms. But how plants budget this resource varies considerably. The kapok trees of the Amazon have adopted vastly different strategies than the switchgrass of the American plains. Unfortunately, it’s hard to directly measure which ones prevail in different ecosystem types and how they shift under changing conditions. Researchers at UC Santa Barbara and San Diego State University recently developed a metric ...

"Scrumping" windfallen fruits and the origin of feasting

2025-07-31
The lives of our earliest hominin ancestors are often shrouded in mystery, but recent research on the consumption of windfallen fruit may shed light on one of humanity's oldest and most savored activities: sharing a good meal (and a tipple) with kith and kin. In a "Notes from the Field" article in the journal BioScience, Nathaniel Dominy (Dartmouth College), Catherine Hobaiter (University of St Andrews), and colleagues coin a new term for gathering and eating fallen fruit: scrumping. The term calls to mind scrumpy, a rustic unfiltered cider popular in the West Country of England. And just as ...

How ‘scrumping’ apes may have given us a taste for alcohol

2025-07-31
If scientists are to better understand whether the genes that let us safely welcome the weekend with a cold beer or enjoy a bottle of wine with dinner began with apes eating fermented fruit, then the habit needs a name, according to a new study. "Scrumping" is the name coined in a paper led by researchers at Dartmouth and the University of St Andrews in Scotland for the fondness apes have for eating ripe fruit from the forest floor. These primates' palate for picked-up produce has taken on new importance in recent years, the researchers report in the journal BioScience. But scientists cannot fully understand the significance of this behavior—particularly ...

Scrumped fruit key to chimpanzee life and a major force of human evolution

2025-07-31
New research from the University of St Andrews and Dartmouth College examines the crucial, but until now, overlooked, role of ‘scrumped’ fruit in the lives of great apes and the origins of human feasting.  Published today (Thursday 31 July) in BioScience, this pioneering study is the first to tackle the mystery of why humans are so astoundingly good at metabolising alcohol.  The findings show that feeding on fermented fruits gathered from the forest floor is an important behaviour in the lives of African apes, ...

Scientists discover new quantum state at the intersection of exotic materials

2025-07-31
Scientists have discovered a new way that matter can exist – one that is different from the usual states of solid, liquid, gas or plasma – at the interface of two exotic, materials made into a sandwich. The new quantum state, called quantum liquid crystal, appears to follow its own rules and offers characteristics that could pave the way for advanced technological applications, the scientists said. Reporting in the journal Science Advances, a Rutgers-led team of researchers described an experiment that focused on the interaction between a conducting material called the Weyl semimetal and an insulating magnetic material known as spin ice when both ...

Healthy food systems: Microbial map reveals countless hidden connections between our food, health, and planet

2025-07-31
*Embargoed paper available on request*  Published in Frontiers in Science, the map of ‘agri-food system microbiomes’ reveals how players at every stage of the food system can restore and protect dwindling microbiomes to help boost human and planetary health.  When microbiomes are diverse and balanced, they keep our food safe, nutritious, and sustainable, and our planet healthy—but the quality of these networks is declining across the whole system. This can be seen in the uptick of antimicrobial resistance (AMR), crop failures, loss of microbial diversity in soil, water, and the human gut, and ...

Microbiome breakthrough: Gut bacterium may hold key to future treatments for widespread chronic diseases

2025-07-31
Our intestines are home to trillions of microorganisms that produce substances capable of regulating all the body’s organs via the bloodstream and the gut’s nervous system. Yet, only little is known about the effects of most of the bacteria that make up our microbiome. Now, an international team of scientists led by the University of Copenhagen has identified a common specific bacterial strain that may open the door to an entirely new class of therapeutics. This bacterium produces two proteins that partly resemble ...

Turning biodiversity upside down: Conservation maps miss fungal hotspots by focusing on plants

2025-07-31
For decades, scientists and conservationists have been using aboveground plant biodiversity as a metric for conserving ecosystems. Now a new study finds that there is a major mismatch between aboveground plant diversity and Earth’s underground fungal biodiversity. A new analysis published in Nature Communications on July 31 focused on the biodiversity mismatches between aboveground vegetation and mycorrhizal fungi – a group of underground fungi that form symbiotic relationships with the roots of 90% of land plants. These fungi help regulate the climate and global nutrient cycles, ...

LAST 30 PRESS RELEASES:

Prevalence, determinants, and time trends of cardiovascular health in the WHO African region

New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers

CNIC-led REBOOT clinical trial challenges 40-year-old standard of care for heart attack patients

Systolic blood pressure and microaxial flow pump–associated survival in infarct-related cardiogenic shock

Beta blockers, the standard treatment after a heart attack, may offer no benefit for heart attack patients and women can have worse outcomes

High Mountain Asia’s shrinking glaciers linked to monsoon changes

All DRII-ed up: How do plants recover after drought?

Research on stigma says to just ‘shake it off’

Scientists track lightning “pollution” in real time using NASA satellite

Millions of women rely on contraceptives, but new Rice study shows they may do more than just prevent pregnancy

Hot days make for icy weather, Philippine study finds

Roxana Mehran, MD, receives the most prestigious award given by the European Society of Cardiology

World's first clinical trial showing lubiprostone aids kidney function

Capturing language change through the genes

Public trust in elections increases with clear facts

Thawing permafrost raised carbon dioxide levels after the last ice age

New DNA test reveals plants’ hidden climate role

Retinitis pigmentosa mouse models reflect pathobiology of human RP59

Cell’s ‘antenna’ could be key to curing diseases

Tiny ocean partnership between algae and bacteria reveals secrets of evolution

Scientists uncover cellular “toolkit” to reprogram immune cells for cancer therapy

Blocking protein control pathway slows rhabdomyosarcoma growth in mice

2026 Hertz Fellowship Application Now Open

The gut immune system is altered in mouse model of Alzheimer’s, providing a new target for therapeutics

ADHD drugs are being prescribed too quickly to preschoolers

UCLA scientists develop off-the-shelf immunotherapy for metastatic kidney cancer

Extreme heat linked to spike in domestic violence calls in New Orleans, study finds

Mount Sinai-Duke University study identifies DNA variants that increase testosterone production in PCOS patients

Physiology-guided complete revascularization in older patients with myocardial infarction

Metals and sulfate in air pollution mixture may contribute most to asthma hospitalizations

[Press-News.org] Immunoglobulin replacement therapy shows no reduction in serious infections for patients with CLL
Findings at odds with increasing use of the therapy in clinical practice